secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2022-11-30T23:59:59+00:00
Accession:  0001193125-22-295406
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic: SYNB1353 achieves proof of mechanism in HCU; cuts workforce 25%
-------------------------------------------------------------------------

- SYNB1353 reduced plasma methionine AUC by -24.8% and -26.2% at 1x10^12 dose vs placebo -2.1% in Phase 1.
- FDA granted Orphan Drug Designation to SYNB1353 for homocystinuria, offering market exclusivity potential.
- Workforce reduced by ~25% to extend cash runway into H2 2024; severance costs estimated at $0.8M.
- Proof-of-concept data for SYNB8802 in enteric hyperoxaluria expected in Q4 2022.
- Phase 3 pivotal study of SYNB1934 for PKU on track to initiate in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312522295406/0001193125-22-295406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312522295406/d421541d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-295406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer